According to the latest report by IMARC Group, titled "Human Microbiome Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027," the global human microbiome market size reached US$ 558.5 Million in 2021. The human microbiome refers to the collection of microbial genomes that contribute to the metagenome of a human. It comprises a diverse array of microorganisms, such as archaea, bacteria, fungi, and nonliving viruses and protozoans. It is a genetic substance that is majorly present in human guts, particularly in the large intestine. It consists of numerous bacteria that aid in food digestion, regulating the immune system and producing vitamins, including B vitamins B12, riboflavin and thiamine, and Vitamin K, which are required for blood coagulation.
Global Human Microbiome Market Trends:
The global market is primarily driven by the rising prevalence of microbial dysbiosis among the masses. Coupled with this, the growing geriatric population, which is prone to chronic ailments, is impacting the market growth favorably. Along with this, extensive research and development (R&D) activities conducted by key players in the field of life science and biotechnology are creating a positive market outlook. In line with this, the increasing focus on immunity development due to the sudden outbreak of the coronavirus disease (COVID-19) is providing an impetus to the market. With the rapid advancements in analytical techniques and sequencing methods that aid in enhancing the ability to gain insights into the human microbiome, this is acting as another major growth-inducing factor. This is due to continuous technological advancements and the growing investments by public and private agencies in upgrading the overall biotechnology infrastructure. Other factors, including rapid digitization and the emerging pharmaceutical industry, are also positively influencing the market. On account of the aforementioned factors, the market is anticipated to reach a value of US$ 1,827.2 Million by 2027, exhibiting a CAGR of 21.9% during 2022-2027.
- On the basis of the product, the market has been segmented into probiotics, prebiotics, diagnostic tests, drugs, medical food and others.
- Based on the application, the market has been classified into therapeutics and diagnostics.
- On the basis of the disease type, the market has been bifurcated into obesity, diabetes, autoimmune disorders, cancer, gastrointestinal disorders, central nervous system disorders and others.
- Based on the region, the market has been divided into North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Latin America (Brazil, Mexico and others) and the Middle East and Africa.
- The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market. Some of the key players include 4D pharma plc, Atlas Biomed Group Limited, BIOHM, BiomX, Bione, DayTwo Inc., ENTEROME, Ferring B.V., Finch Therapeutics, Second Genome Inc., SynBioBeta LLC, Synthetic Biologics Inc., Vedanta Biosciences Inc. and Viome Inc.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St, Ste
Sheridan, WY (Wyoming) 82801 USA
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800